Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Endosomolytic bioreducible poly(amido amine disulfide) polymer conjugates for the in vivo systemic delivery of siRNA therapeutics.

Parmar RG, Busuek M, Walsh ES, Leander KR, Howell BJ, Sepp-Lorenzino L, Kemp E, Crocker LS, Leone A, Kochansky CJ, Carr BA, Garbaccio RM, Colletti SL, Wang W.

Bioconjug Chem. 2013 Apr 17;24(4):640-7. doi: 10.1021/bc300600a. Epub 2013 Mar 25.

PMID:
23496378
2.

10-Hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones: potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutants.

Wiscount CM, Williams PD, Tran LO, Embrey MW, Fisher TE, Sherman V, Homnick CF, Donnette Staas D, Lyle TA, Wai JS, Vacca JP, Wang Z, Felock PJ, Stillmock KA, Witmer MV, Miller MD, Hazuda DJ, Day AM, Gabryelski LJ, Ecto LT, Schleif WA, DiStefano DJ, Kochansky CJ, Anari MR.

Bioorg Med Chem Lett. 2008 Aug 15;18(16):4581-3. doi: 10.1016/j.bmcl.2008.07.037. Epub 2008 Jul 15.

PMID:
18657970
3.

Impact of pH on plasma protein binding in equilibrium dialysis.

Kochansky CJ, McMasters DR, Lu P, Koeplinger KA, Kerr HH, Shou M, Korzekwa KR.

Mol Pharm. 2008 May-Jun;5(3):438-48. doi: 10.1021/mp800004s. Epub 2008 Mar 18.

PMID:
18345638
4.

8-Hydroxy-3,4-dihydropyrrolo[1,2-a]pyrazine-1(2H)-one HIV-1 integrase inhibitors.

Fisher TE, Kim B, Staas DD, Lyle TA, Young SD, Vacca JP, Zrada MM, Hazuda DJ, Felock PJ, Schleif WA, Gabryelski LJ, Anari MR, Kochansky CJ, Wai JS.

Bioorg Med Chem Lett. 2007 Dec 1;17(23):6511-5. Epub 2007 Sep 29.

PMID:
17931865
5.

Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.

Beconi MG, Reed JR, Teffera Y, Xia YQ, Kochansky CJ, Liu DQ, Xu S, Elmore CS, Ciccotto S, Hora DF, Stearns RA, Vincent SH.

Drug Metab Dispos. 2007 Apr;35(4):525-32. Epub 2007 Jan 12.

6.

The role of P-glycoprotein in the bioactivation of raloxifene.

Chang JH, Kochansky CJ, Shou M.

Drug Metab Dispos. 2006 Dec;34(12):2073-8. Epub 2006 Sep 7.

7.

Discovery of potent, selective 4-fluoroproline-based thrombin inhibitors with improved metabolic stability.

Staas DD, Savage KL, Sherman VL, Shimp HL, Lyle TA, Tran LO, Wiscount CM, McMasters DR, Sanderson PE, Williams PD, Lucas BJ Jr, Krueger JA, Lewis SD, White RB, Yu S, Wong BK, Kochansky CJ, Anari MR, Yan Y, Vacca JP.

Bioorg Med Chem. 2006 Oct 15;14(20):6900-16. Epub 2006 Jul 25.

PMID:
16870455
8.

Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans.

Kochansky CJ, Rippley RK, Yan KX, Song H, Wallace MA, Dean D, Jones AN, Lasseter K, Schwartz J, Vincent SH, Franklin RB, Wagner J.

Drug Metab Dispos. 2006 Sep;34(9):1457-61. Epub 2006 Jun 13.

9.

Species differences in the elimination of a peroxisome proliferator-activated receptor agonist highlighted by oxidative metabolism of its acyl glucuronide.

Kochansky CJ, Xia YQ, Wang S, Cato B, Creighton M, Vincent SH, Franklin RB, Reed JR.

Drug Metab Dispos. 2005 Dec;33(12):1894-904. Epub 2005 Sep 23.

10.

Increasing the efficiency of in-capillary electrophoretically mediated microanalysis reactions via rapid polarity switching.

Sanders BD, Slotcavage RL, Scheerbaum DL, Kochansky CJ, Strein TG.

Anal Chem. 2005 Apr 15;77(8):2332-7.

13.
14.

Determination of uremic toxins in biofluids: creatinine, creatine, uric acid and xanthines.

Kochansky CJ, Strein TG.

J Chromatogr B Biomed Sci Appl. 2000 Sep 29;747(1-2):217-27. Review.

PMID:
11103907

Supplemental Content

Loading ...
Support Center